stoxline Quote Chart Rank Option Currency Glossary
Homology Medicines, Inc. (FIXX)
0.575  0.035 (6.48%)    12-07 16:00
Open: 0.5303
High: 0.5899
Volume: 347,760
Pre. Close: 0.54
Low: 0.5303
Market Cap: 33(M)
Technical analysis
2023-12-07 4:20:39 PM
Short term     
Mid term     
Targets 6-month :  0.99 1-year :  1.27
Resists First :  0.84 Second :  1.09
Pivot price 0.55
Supports First :  0.45 Second :  0.38
MAs MA(5) :  0.55 MA(20) :  0.66
MA(100) :  1.04 MA(250) :  1.12
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  21.2 D(3) :  17.3
RSI RSI(14): 30.5
52-week High :  1.75 Low :  0.45
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FIXX ] has closed below upper band by 7.8%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.59 - 0.59 0.59 - 0.6
Low: 0.52 - 0.53 0.53 - 0.53
Close: 0.57 - 0.57 0.57 - 0.58
Company Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Headline News

Fri, 17 Nov 2023
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire

Thu, 16 Nov 2023
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to ... - Business Wire

Thu, 16 Nov 2023
Big Pharma-backed startup to go public by merging with gutted Homology - Boston Business Journal - The Business Journals

Thu, 16 Nov 2023
Why Is Rare Disease Focused Homology Medicines (FIXX) Stock Trading Lower Today? - Homology Medicines (NA - Benzinga

Thu, 16 Nov 2023
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely - Simply Wall St

Thu, 16 Nov 2023
Q32 Bio and Homology Medicines Announce Merger Agreement - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 58 (M)
Held by Insiders 3.091e+007 (%)
Held by Institutions 9.1 (%)
Shares Short 307 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1631e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 984.7 %
Return on Equity (ttm) -36.4 %
Qtrly Rev. Growth 1.96e+006 %
Gross Profit (p.s.) -2795
Sales Per Share -3667.5
EBITDA (p.s.) -4.757e+009
Qtrly Earnings Growth -2.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -102 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 297770
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android